Epidermolysis Bullosa Simplex
17
4
4
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
5.9%
1 terminated out of 17 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (17)
A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized
Computational Drug Repurposing for All EBS Cases
Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex
Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex
INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita